SCHEMBL1827469

SCHEMBL1827469

Cc1nocc1C(=O)Nc1ccc(-c2cc(C(F)(F)F)ccc2C(F)(F)F)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.46
GMNN O75496 1/20 0.46
LMNA P02545 1/20 0.46
TP53 P04637 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
HTR1A P08908 1/20 0.46
THRB P10828 1/20 0.46
PIM1 P11309 1/20 0.46
CYP2C9 P11712 1/20 0.46
MAOA P21397 1/20 0.46
SLC6A2 P23975 1/20 0.46
HTR2A P28223 1/20 0.46
AGTR1 P30556 1/20 0.46
CCKBR P32239 1/20 0.46
MC4R P32245 1/20 0.46
CYP2C19 P33261 1/20 0.46
THPO P40225 1/20 0.46
HTT P42858 1/20 0.46
RAB9A P51151 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16363170 0.90 TRPV1 (0.44) NPC1GMNNLMNATP53CYP1A2
SCHEMBL3670697 0.85 SMN1; SMN2 (0.60) NPC1GMNNLMNATP53CYP1A2
SCHEMBL2785720 0.82 KDR (0.38) CYP3A4CYP2C9RAB9ASMN1; SMN2NPSR1
SCHEMBL1826603 0.81 GFER (0.52) NPC1GMNNLMNATP53CYP1A2
SCHEMBL1828980 0.81 TRPV1 (0.57) TRPV1
SCHEMBL1826746 0.81 RAB9A (0.73) NPC1GMNNLMNATP53CYP1A2
SCHEMBL6707284 0.81 FLT1 (0.51) NPC1GMNNLMNATP53CYP1A2
SCHEMBL1826804 0.81 NPC1 (0.56) NPC1GMNNLMNATP53CYP1A2
SCHEMBL8297621 0.80 RXFP1 (0.57) NPC1LMNATP53THRBRAB9A
SCHEMBL1828082 0.79 IL2 (0.48) NPC1GMNNLMNATP53CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2319516-A1 Compounds for treating inflammatory and autoimmune disorders Synta Pharmaceuticals Corp. (US) 2011-05-11 EP disclosed
EP-2319516-A1 Compounds for treating inflammatory and autoimmune disorders Synta Pharmaceuticals Corp. (US) 2011-05-11 EP disclosed
WO-2005009954-A2 METHOD FOR MODULATING CALCIUM ION-RELEASE-ACTIVATED CALCIUM ION CHANNELS SYNTA PHARMACEUTICALS, CORP. (US) 2005-02-03 WO disclosed
WO-2005009539-A2 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS, CORP. (US) 2005-02-03 WO disclosed